Navigation Links
Signal Genetics Announces Publication of Meta-Analysis of its Colon Cancer Test-Previstage™ GCC Confirming Prognostic Capabilities in Patients with Colon Cancer
Date:1/23/2012

NEW YORK, Jan. 23, 2012 /PRNewswire/ -- Signal Genetics, a privately held personalized medicine company focused on cancer, announced today the presentation of a paper entitled "Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis" at the 2012 American Society of Clinical Oncology Gastrointestinal Cancer Symposium held in San Francisco, CA January 21, 2012.  The data from the paper demonstrate the value of implementing Previstage testing in patients with colorectal cancer to identify those patients at risk of relapse.

The paper is the culmination of the work conducted by a team of researchers and  collaborators from several  centers, including:  Rhode Island Hospital, Brown University, University of Massachusetts  Medical School, University of North Carolina, Lahey Clinic, Brigham and Women's Hospital, British Columbia Cancer Agency and DiagnoCure Inc.  These researchers conducted a pooled individual data analysis on 310 patients to confirm whether molecular detection of GCC in Lymph Nodes indicates high risk of disease recurrence and poor survival in untreated stage II colon cancer.

GCC is a colon-specific biomarker normally found in gastrointestinal epithelium whose expression is preserved in primary and metastatic colorectal cancer cells. Studies to date have suggested that the presence of GCC gene expression in lymph nodes increased the likelihood of disease recurrence in stage II colon cancer patients, independent of traditional high risk features. The results of this study suggest that detection of GCC mRNA in lymph nodes is associated with risk of disease recurrence in stage II colon cancer patients not treated with adjuvant chemotherapy.  These findings are consistent with several other studies conducted over the past 10 years.

Based on GCC levels, the estimated 5 year recurrence risks were 11% and 32% for the low and high risk groups respectively, clearly showing that GCC is a strong prognostic marker that effectively stratifies patients between those that are essentially cured from those at risk of disease recurrence. Higher detection levels of GCC in lymph nodes is also significantly associated with increased risk of all-cause mortality, disease-specific survival, and disease-free survival. 

According to Joe Hernandez, President and CEO of Signal Genetics, "This paper represents further validation of GCC as a strong prognostic test that provides physicians and their patients an important insight that helps them make critical treatment decisions." 

About Signal Genetics.
Signal Genetics, the parent company of Myeloma Health, Respira Health, and CC Health, is a privately held personalized medicine genetic testing company focused on bringing novel insights to physicians and their patients with various types of cancer.  The goal of Signal Genetics is to provide information regarding disease status, stage, odds of relapse, predicting response to therapy, and prognosis through an array of proprietary tools to help guide physicians to the optimal treatment for each individual patient. Additional information is available at www.signalgenetics.com.


'/>"/>
SOURCE Signal Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signal Genetics Announces Launch of Next Generation Genetic Multiple Myeloma Predictive Testing Product-MyPRS Plus™
2. New Gene Study of ADHD Points to Defects in Brain Signaling Pathways
3. USPTO Issues Patent for CardioGenics Signal Amplification Technology
4. Signal Genetics and DiagnoCure Announce a US$13.3M Collaboration for the Commercialization of Previstage™ GCC Colorectal Cancer Staging Test
5. Signal Genetics Announces Commercialization Partnership with NeoGenomics Laboratories for Multiple Myeloma Gene Expression Test
6. Quantum Signal and Delphinus Medical Technologies Awarded MEGA Funding to Expand in Ann Arbor Area
7. Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
8. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
9. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
10. Device Blocking Stomach Nerve Signals Shows Promise in Obesity
11. Grocery Manufacturers Association: Study Signals Progress in Battle Against Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)...  Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... July 28, 2017, beginning at 7:30 a.m. (CDT) / 8:30 ... To participate in the conference call, dial (877) 304-8969 (domestic) ... least 10 minutes prior to the start to allow time ... Webcast: A simultaneous webcast of the ...
(Date:6/16/2017)... , June 16, 2017  Exactly 50 years ago ... off what later became known as the San Francisco "Summer ... ) is unveiling two radical innovations in strategic market research ... This announcement marks the beginning of Northern Light,s "Summer of ... ...
(Date:6/14/2017)... -- In 2016, Embodied Labs took top prize ... came away with $25,000 in seed-fund investment. Embodied Labs ... "entering the life of another" and by the Journal ... medical professionals in an entirely new dimension." Building upon ... for the Department of Education,s EdSimChallenge, where they received ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... 24, 2017 , ... The weather is heating up and the days are ... should be aware that the summer months provide more than warmer temperatures that are ... can be negatively affected from direct exposure to the sun. When it comes to ...
(Date:6/23/2017)... , ... June 23, 2017 , ... By scoring 100% ... ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's work ... 1% of all charities reviewed by Charity Navigator and earns ANRF a spot on ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... plastic surgeon practicing in Newburgh, New York, has recently begun offering three new ... to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited ...
(Date:6/23/2017)... Hills, CA (PRWEB) , ... June 23, 2017 , ... ... plane facelift . Dr. Talei has come up with a proprietary technique that ... releases and lifts tissues that have dropped. For all ages, patients can expect to ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... MD ... Florida. This is MD Now’s 28th facility overall and marks the urgent care center's ... located one mile North of The Falls shopping mall. The new clinic offers a ...
Breaking Medicine News(10 mins):